Cargando…

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia

Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valen...

Descripción completa

Detalles Bibliográficos
Autores principales: Haggenburg, Sabine, Garcia Garrido, Hannah M., Kant, Iris M. J., Van der Straaten, Hanneke M., De Boer, Fransien, Kersting, Sabina, Issa, Djamila, Te Raa, Doreen, Visser, Hein P. J., Kater, Arnon P., Goorhuis, Abraham, De Heer, Koen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385862/
https://www.ncbi.nlm.nih.gov/pubmed/37515017
http://dx.doi.org/10.3390/vaccines11071201
_version_ 1785081517026836480
author Haggenburg, Sabine
Garcia Garrido, Hannah M.
Kant, Iris M. J.
Van der Straaten, Hanneke M.
De Boer, Fransien
Kersting, Sabina
Issa, Djamila
Te Raa, Doreen
Visser, Hein P. J.
Kater, Arnon P.
Goorhuis, Abraham
De Heer, Koen
author_facet Haggenburg, Sabine
Garcia Garrido, Hannah M.
Kant, Iris M. J.
Van der Straaten, Hanneke M.
De Boer, Fransien
Kersting, Sabina
Issa, Djamila
Te Raa, Doreen
Visser, Hein P. J.
Kater, Arnon P.
Goorhuis, Abraham
De Heer, Koen
author_sort Haggenburg, Sabine
collection PubMed
description Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23). Because both CLL as well as immunosuppressive treatment have been identified as major determinants of immunogenicity, we aimed to assess the vaccination schedule in untreated and treated CLL patients. We quantified pneumococcal IgG concentrations against five serotypes shared across both vaccines, and against four serotypes unique to PPSV23, before and eight weeks after vaccination. In this retrospective cohort study, we included 143 CLL patients, either treated (n = 38) or naive to treatment (n = 105). While antibody concentrations increased significantly after vaccination, the overall serologic response was low (10.5%), defined as a ≥4-fold antibody increase against ≥70% of the measured serotypes, and significantly influenced by treatment status and prior lymphocyte number. The serologic protection rate, defined as an antibody concentration of ≥1.3 µg/mL for ≥70% of serotypes, was 13% in untreated and 3% in treated CLL patients. Future research should focus on vaccine regimens with a higher immunogenic potential, such as multi-dose schedules with higher-valent T cell dependent conjugated vaccines.
format Online
Article
Text
id pubmed-10385862
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103858622023-07-30 Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia Haggenburg, Sabine Garcia Garrido, Hannah M. Kant, Iris M. J. Van der Straaten, Hanneke M. De Boer, Fransien Kersting, Sabina Issa, Djamila Te Raa, Doreen Visser, Hein P. J. Kater, Arnon P. Goorhuis, Abraham De Heer, Koen Vaccines (Basel) Article Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23). Because both CLL as well as immunosuppressive treatment have been identified as major determinants of immunogenicity, we aimed to assess the vaccination schedule in untreated and treated CLL patients. We quantified pneumococcal IgG concentrations against five serotypes shared across both vaccines, and against four serotypes unique to PPSV23, before and eight weeks after vaccination. In this retrospective cohort study, we included 143 CLL patients, either treated (n = 38) or naive to treatment (n = 105). While antibody concentrations increased significantly after vaccination, the overall serologic response was low (10.5%), defined as a ≥4-fold antibody increase against ≥70% of the measured serotypes, and significantly influenced by treatment status and prior lymphocyte number. The serologic protection rate, defined as an antibody concentration of ≥1.3 µg/mL for ≥70% of serotypes, was 13% in untreated and 3% in treated CLL patients. Future research should focus on vaccine regimens with a higher immunogenic potential, such as multi-dose schedules with higher-valent T cell dependent conjugated vaccines. MDPI 2023-07-04 /pmc/articles/PMC10385862/ /pubmed/37515017 http://dx.doi.org/10.3390/vaccines11071201 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Haggenburg, Sabine
Garcia Garrido, Hannah M.
Kant, Iris M. J.
Van der Straaten, Hanneke M.
De Boer, Fransien
Kersting, Sabina
Issa, Djamila
Te Raa, Doreen
Visser, Hein P. J.
Kater, Arnon P.
Goorhuis, Abraham
De Heer, Koen
Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
title Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
title_full Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
title_fullStr Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
title_full_unstemmed Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
title_short Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
title_sort immunogenicity of the 13-valent pneumococcal conjugated vaccine followed by the 23-valent polysaccharide vaccine in chronic lymphocytic leukemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385862/
https://www.ncbi.nlm.nih.gov/pubmed/37515017
http://dx.doi.org/10.3390/vaccines11071201
work_keys_str_mv AT haggenburgsabine immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT garciagarridohannahm immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT kantirismj immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT vanderstraatenhannekem immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT deboerfransien immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT kerstingsabina immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT issadjamila immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT teraadoreen immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT visserheinpj immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT katerarnonp immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT goorhuisabraham immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia
AT deheerkoen immunogenicityofthe13valentpneumococcalconjugatedvaccinefollowedbythe23valentpolysaccharidevaccineinchroniclymphocyticleukemia